Ludwig Enterprises, Inc. (LUDG): R&D Expense

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2023-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$231.6K

Year ended 2025-12-31

$166.7K

Trailing 12 months to 2026-03-31

2022-12-31 R&D Expense (USD) 2025-12-31

Period ended	R&D Expense	Change YoY	Source filing
2025-12-31	$231.6K	+39.8%	2026-03-16, From 2025-01-01
2024-12-31	$165.6K	-59.7%	2026-03-16, From 2024-01-01
2023-12-31	$411.0K	n/c	2025-03-31, From 2023-01-01
2022-12-31	$113.2K	n/a	2024-04-16, From 2022-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Services-Medical Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	R&D Expense	Change YoY
Ludwig Enterprises, Inc. (LUDG)	2025-12-31	$231.6K	+39.8%
Advanced Biomed Inc. (ADVB)	2025-06-30	$909.8K	+3.4%
BioNexus Gene Lab Corp (BGLC)	2025-12-31	$50.7K	+6.6%
Aclarion, Inc. (ACON)	2025-12-31	$1.03M	+16.3%
YD Bio Ltd (YDES)	2025-12-31	$1.60M	+226.1%
Exagen Inc. (XGN)	2025-12-31	$6.25M	+16.4%
Biodesix Inc (BDSX)	2025-12-31	$12.00M	+25.5%
Sera Prognostics, Inc. (SERA)	2025-12-31	$13.17M	-10.6%
Personalis, Inc. (PSNL)	2025-12-31	$50.26M	+2.8%

Compare LUDG, ADVB, BGLC, ACON side by side · Screen every company in Services-Medical Laboratories ↗